Missing protein in rare genetic brain disorder restored

Washington, Sep 7 (ANI): By using protease inhibitors, researchers at the University of California-San Francisco (UCSF) have restored to normal levels a key protein that is involved in early brain development, and causes the rare brain disorder lissencephaly.

Reduced levels of the protein called LIS1 have been shown to cause lissencephaly, which is characterized by brain malformations, seizures, severe mental retardation and very early death in human infants.

The findings in mice offer a proof-of-principle that the genetic equivalent to human lissencephaly, also known as “smooth brain” disease, can be treated during pregnancy and effectively reversed to produce more normal offspring.

The researchers are hoping that this approach could also be used to treat other defects in utero, or even those manifesting after birth, when caused by a partial deficiency in one gene, according to Dr. Anthony Wynshaw-Boris.

“Researchers have not considered it possible to treat such a pervasive, early developmental brain disorder as lissencephaly. Not only were we able to show a clear cellular effect from using these protease inhibitors, but also were able to treat the disorder in utero,” Nature quoted Wynshaw-Boris as saying.

The work is the culmination of 15 years of collaborative research into the cause and mechanisms of lissencephaly, which is caused by a deletion or loss of one copy of the LIS1 gene, and affects an estimated one in 50,000-100,000 infants.

In 1998, the researchers reported of producing a mouse with the same mutation that displayed defective brain development.

The current research used these mice, and found that the protein calpain degrades the LIS1 protein to less than half its normal levels near the surface of the cells.

The team then used a specific small-molecule protease inhibitor of calpain in these mice.

At a cellular level, the protease inhibitors enabled LIS1 protein to be expressed at near-normal levels.

The team then gave daily injections of a calpain inhibitor to pregnant mice whose foetuses had the mouse-model of this defect.

They observed that the resulting offspring had more normal brains and showed no sign of mental retardation.

“This study is really a proof-of-principle not only for treating complex developmental brain disorders, but also for any disorder with reduced protein levels where proteases normally play some role in breaking down that protein. This will be much more difficult to apply to humans, because of the safety issues involved, but it could lead to new therapies that might be effective for a wide range of developmental disorders,” said the researchers.

The findings have been published in the journal Nature Medicine. (ANI)

Key component in preeclampsia development identified

Washington, Sep 5 (ANI): Researchers at Wake Forest University School of Medicine have found a key contributor in the development of preeclampsia in pregnant women – a condition that can result in miscarriage and maternal death.

The researchers in the study focused on identifying the differences in the uteri of pregnant women with and without preeclampsia and how the mother’s tissues vary from the immediately adjacent foetus’ tissue in preeclamptic women.

“Preeclampsia is a very serious condition that affects 7 to 10 percent of all pregnancies in the United States. It can be devastating to both mother and baby, and currently there is no cure except to deliver the fetus. Our finding brings us one step closer to understanding the condition by getting a picture of what is happening at the maternal and fetal interface,” said Dr. K. Bridget Brosnihan, the lead investigator for the study.

Preeclampsia is a rapidly progressive condition that impacts multiple body systems, causing high blood pressure, decreased liver function and, in the most severe cases, affecting the activity of the brain, resulting in seizures.

If left untreated, preeclampsia can lead to serious, even fatal, complications for both mother and baby.

Despite numerous studies, researchers have only closed down on one possible pathway-the renin-angiotensin system (RAS), which regulates blood pressure and fluid retention.

The RAS, when operating normally, forms a hormone called angiotensin II- a potent vasoconstrictor that binds to angiotensin II receptors throughout the body, including in the maternal uterine “bed” and the fetal placenta.

It causes the muscular walls of blood vessels to contract, narrowing the diameter of the vessels and increasing blood pressure.

In normal pregnancy, the uterus has lower RAS activity, producing less angiotensin II, which results in the blood vessels remaining dilated.

This leads to lower blood pressure and allows more oxygen and nutrients to pass from the mother’s uterus to the placenta and foetus, which is beneficial for its development.

However, in preeclamptic women, the activity of the RAS is increased in the uterus, yet the mother’s vessels remain dilated and the fetus’ vessels constrict more than normal.

Brosnihan and colleagues focused on uncovering the reason for this in the current study and found that the angiotensin II receptors are not detectable in the uteri of pregnant or preeclamptic women.

In normal pregnancy, this does not present a problem because there is less angiotensin II being produced, making the receptors less important.

However, in preeclamptic women, where uterine angiotensin II is high, the hormone does not bind to its receptors in the uterus as it should.

Instead, it passes through to the vessels of the foetal placenta and constricts the foetus’ vessels, limiting the foetus’ oxygen and nutrient intake and often causing low birth weight.

The only known way to cure preeclampsia is delivery of the baby.

Inhibitors of the RAS are known to have bad effects on the foetus, so controlling the system is difficult in preeclamptic women, said Brosnihan.

“It is very hard to control parts of this system to prevent preeclampsia without hurting the baby. Our study provides some insight into maternal factors that may augment the disease. Hopefully, one day, we will be closer to finding a cure,” said Brosnihan.

The study has been published in the September issue of Endocrinology. (ANI)

Scientists identify promising compound to treat epilepsy

Washington, May 5 (ANI): Scientists have identified a new anticonvulsant compound, called paxilline, which may cease the progression of epilepsy, a neurological disorder marked by abnormal electrical activity in the brain that leads to recurring seizures.

The study by Carnegie Mellon University researchers is based on a previous work in which scientists identified a specific molecular target whose increased activity is linked with seizure disorders- a potassium channel known as the BK channel.
“We have found a new anticonvulsant compound that eliminates seizures in a model of epilepsy,” said Alison Barth, associate professor of biological sciences at Carnegie Mellon’s Mellon College of Science.

She added: “The drug works by inhibiting ion channels whose role in epilepsy was only recently discovered. Understanding how these channels work in seizure disorders, and being able to target them with a simple treatment, represents a significant advance in our ability to understand and treat epilepsy.” he researchers found that after a first seizure, BK channel function was markedly enhanced.

Thus, the neurons became overly excitable and were firing with more speed, intensity and spontaneity, which led the researchers to believe that the abnormal increase in the activity of the channels might play a role in causing subsequent seizures and the emergence of epilepsy. n the current study, the researchers tested this theory by blocking the ion channels using a BK-channel antagonist called paxilline.

Using an experimental model for epilepsy, Barth tested whether paxilline could reduce or prevent experimentally induced seizures, as it could normalize aberrant brain activity induced by previous seizures.

And to their surprise, the researchers discovered that the compound was effective at completely blocking subsequent seizures. The drug is orally available, and works in the low nanomolar range,” said Barth.

As the drug is effective in low concentrations and can be taken as a pill, it could turn out to be an especially promising compound for treatment in epilepsy patients.

The researchers believe that targeting the BK channels and the abnormal brain activity that they induce might one day be used as a way to prevent the progression of seizure disorders over time, thus attacking the root cause of epilepsy.

The findings have been published in the current issue of the journal Epilepsia. (ANI)

Gene that switches on during epilepsy development identified

Washington, Apr 23 (ANI): Researchers at Wake Forest University School of Medicine have identified a gene that switches on during development of epilepsy.

The discovery made while studying mice may help explain how some people without a genetic predisposition to epilepsy can develop the disorder.

In a study published this month in the Journal of Neuroscience, senior researcher Dwayne W. Godwin, Ph.D., a professor of neurobiology and anatomy, and colleagues, report discovering that a gene, already known to predispose people who inherit an active form of it to certain forms of epilepsy, can actually be “switched on” in animals that do not appear to have inherited the active form, and therefore a genetic predisposition, to the condition.

The gene codes a calcium channel in the brain that underlies seizures, so the finding may reveal a mechanism by which epilepsy develops in those with no apparent genetic predisposition to it.

“Epilepsy is a terrible disorder that affects millions of kids and adults all over the world,” Godwin said.

“There are many different forms of epilepsy with different symptoms. We don’t know why some people acquire epilepsy – the cause isn’t always clear from the person’s genetic makeup. We do know that in some forms of epilepsy, once someone has a seizure they tend to have more. Our findings from this study suggest that something about the brain changes that can lead to this increased tendency to have a seizure. Our study shows that an important change occurs in calcium channels that help to transmit this abnormal activity throughout the brain,” the expert added.

Calcium channels come in a variety of forms throughout the body and are responsible for several key functions, depending on their placement and quantity. The calcium channels in the brain are normally embedded within the membrane of brain cells, where they allow passage of calcium ions into the cell and are responsible for the electrical activity of the brain.

The passage of calcium ions into cells determines how excitable the cells are, and how easily abnormal activity spreads through the brain.

If, as in epilepsy, a particular channel shows up where it is not supposed to or appears in too many or too few numbers, the function that channel is responsible for can become abnormal. Researchers know that during epileptic seizures, these calcium channels in the brain, responsible for generating electrical brain rhythms, become highly active.

For the study, researchers used a mouse model to observe changes in tissue from regions of the brain that are involved in seizures, the hippocampus and the thalamus. They measured these changes at different time intervals as the mice developed epilepsy. The researchers found that after an initial seizure, more of this particular kind of calcium channel begins to be expressed where it wasn’t before, and the presence of the channel caused brain activity to become increasingly abnormal and epileptic.

“Calcium channels underlie valuable functions. But in the wrong place, at the wrong time, or in the wrong amount, their presence can be disruptive. In the context of brain circuits, the brain cells that have too many copies of the channel get over excited and respond abnormally,” Godwin said.

While the hippocampus is usually targeted in studies of epilepsy, the new channels were being made in a region of the brain called the thalamus. The thalamus is connected to the hippocampus and is involved in the spread of seizures throughout the brain.

“Certain kinds of channels are normal and expected in the thalamus, but after an initial seizure more copies of a channel that isn’t normally found in this brain region begin to appear,” explained graduate student John Graef, the first author on the study.

“The brain activity then becomes dominated by the new copies of this channel. It helps explain how seizures can develop and spread,” the expert added. (ANI)